title: Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries.
abstract: BACKGROUND
  Microvascular renal and retinal diseases are common major complications of type 2 diabetes mellitus. The relation between plasma lipids and microvascular disease is not well established.
  
  
  RESULTS
  The case subjects were 2535 patients with type 2 diabetes mellitus with an average duration of 14 years, 1891 of whom had kidney disease and 1218 with retinopathy. The case subjects were matched for diabetes mellitus duration, age, sex, and low-density lipoprotein cholesterol to 3683 control subjects with type 2 diabetes mellitus who did not have kidney disease or retinopathy. The study was conducted in 24 sites in 13 countries. The primary analysis included kidney disease and retinopathy cases. Matched analysis was performed by use of site-specific conditional logistic regression in multivariable models that adjusted for hemoglobin A1c, hypertension, and statin treatment. Mean low-density lipoprotein cholesterol concentration was 2.3 mmol/L. The microvascular disease odds ratio increased by a factor of 1.16 (95% confidence interval, 1.11-1.22) for every 0.5 mmol/L (≈1 quintile) increase in triglycerides or decreased by a factor of 0.92 (0.88-0.96) for every 0.2 mmol/L (≈1 quintile) increase in high-density lipoprotein cholesterol. For kidney disease, the odds ratio increased by 1.23 (1.16-1.31) with triglycerides and decreased by 0.86 (0.82-0.91) with high-density lipoprotein cholesterol. Retinopathy was associated with triglycerides and high-density lipoprotein cholesterol in matched analysis but not significantly after additional adjustment.
  
  
  CONCLUSIONS
  Diabetic kidney disease is associated worldwide with higher levels of plasma triglycerides and lower levels of high-density lipoprotein cholesterol among patients with good control of low-density lipoprotein cholesterol. Retinopathy was less robustly associated with these lipids. These results strengthen the rationale for studying dyslipidemia treatment to prevent diabetic microvascular disease.
authors.affiliation: Nutrition Department, Harvard School of Public Health, Boston, MA (F.M.S., L.B.); Cliniques universitaires Saint Luc, Université catholique de Louvain, Brussels, Belgium (M.P.H.); Department of Medicine, University of Padova, Padova, Italy (P.F., I.B.); Department of Endocrinology Diabetology Nutrition, Jean Verdier Hospital, AP-HP, Le Centre de Recherché en Nutrition Humaine d'Ille de France, Paris Nord University, Bondy, France (P.V.); University of Western Australia, Crawley, Australia (T.D.); Harvard Medical School, Joslin Diabetes Center, Boston, MA (E.H., S.H.-B.); University of Würzburg, Würzburg, Germany (C.W.); College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia (K.A.-R.); LMC Diabetes and Endocrinology, Toronto, Ontario, Canada (R.A.); Department of Medicine, Section of Endocrinology, University of Verona, Verona, Italy (E.B., G.Z.); Ramathibodi Hospital, Bangkok, Thailand (P.B.); Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan (L.-M.C., Y.-D.J.); Rangsit School of Medicine, Rajavithi Hospital, Bangkok, Thailand (C.D.); North York General Hospital and LMC Diabetes and Endocrinology Centres, Toronto, Ontario, Canada (R.G.); Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA (B.H., N.L., V.J.C.); CIBERDEM and Vall d'Hebron Research Institute, Barcelona, Spain (C.H., R.S.); Keio University School of Medicine, Tokyo, Japan (H.I., M.T.); Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Jiaotong University, Affiliated Sixth People's Hospital, Shanghai, China (W.J.); Department of Diabetes and Metabolic Diseases, The University of Tokyo, Tokyo, Japan (T.K.); University of Toronto, Toronto, Ontario, Canada (L.L.); Tokyo Medical University, Tokyo, Japan (T.M., M.O.); Department of General Internal Medicine, National Cancer Center Hospital, Tokyo, Japan (K.O.); Tokyo Medical University Hachioji Medical Center, Tokyo, Japan (A.O.); Beijing 301 Mili
authors.forename: Frank M
authors.initials: FM
authors.lastname: Sacks
authors.forename: Michel P
authors.initials: MP
authors.lastname: Hermans
authors.forename: Paola
authors.initials: P
authors.lastname: Fioretto
authors.forename: Paul
authors.initials: P
authors.lastname: Valensi
authors.forename: Timothy
authors.initials: T
authors.lastname: Davis
authors.forename: Edward
authors.initials: E
authors.lastname: Horton
authors.forename: Christoph
authors.initials: C
authors.lastname: Wanner
authors.forename: Khalid
authors.initials: K
authors.lastname: Al-Rubeaan
authors.forename: Ronnie
authors.initials: R
authors.lastname: Aronson
authors.forename: Isabella
authors.initials: I
authors.lastname: Barzon
authors.forename: Louise
authors.initials: L
authors.lastname: Bishop
authors.forename: Enzo
authors.initials: E
authors.lastname: Bonora
authors.forename: Pongamorn
authors.initials: P
authors.lastname: Bunnag
authors.forename: Lee-Ming
authors.initials: LM
authors.lastname: Chuang
authors.forename: Chaicharn
authors.initials: C
authors.lastname: Deerochanawong
authors.forename: Ronald
authors.initials: R
authors.lastname: Goldenberg
authors.forename: Benjamin
authors.initials: B
authors.lastname: Harshfield
authors.forename: Cristina
authors.initials: C
authors.lastname: Hernández
authors.forename: Susan
authors.initials: S
authors.lastname: Herzlinger-Botein
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Itoh
authors.forename: Weiping
authors.initials: W
authors.lastname: Jia
authors.forename: Yi-Der
authors.initials: YD
authors.lastname: Jiang
authors.forename: Takashi
authors.initials: T
authors.lastname: Kadowaki
authors.forename: Nancy
authors.initials: N
authors.lastname: Laranjo
authors.forename: Lawrence
authors.initials: L
authors.lastname: Leiter
authors.forename: Takashi
authors.initials: T
authors.lastname: Miwa
authors.forename: Masato
authors.initials: M
authors.lastname: Odawara
authors.forename: Ken
authors.initials: K
authors.lastname: Ohashi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ohno
authors.forename: Changyu
authors.initials: C
authors.lastname: Pan
authors.forename: Jiemin
authors.initials: J
authors.lastname: Pan
authors.forename: Juan
authors.initials: J
authors.lastname: Pedro-Botet
authors.forename: Zeljko
authors.initials: Z
authors.lastname: Reiner
authors.forename: Carlo Maria
authors.initials: CM
authors.lastname: Rotella
authors.forename: Rafael
authors.initials: R
authors.lastname: Simo
authors.forename: Masami
authors.initials: M
authors.lastname: Tanaka
authors.forename: Eugenia
authors.initials: E
authors.lastname: Tedeschi-Reiner
authors.forename: David
authors.initials: D
authors.lastname: Twum-Barima
authors.forename: Giacomo
authors.initials: G
authors.lastname: Zoppini
authors.forename: Vincent J
authors.initials: VJ
authors.lastname: Carey
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D008076:Cholesterol, HDL / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications*; D003928:Diabetic Nephropathies / Q000097:blood / Q000453:epidemiology* / Q000209:etiology; D003930:Diabetic Retinopathy / Q000097:blood / Q000453:epidemiology* / Q000209:etiology; D050171:Dyslipidemias / Q000517:prevention & control; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D015994:Incidence; D038622:Internationality; D008297:Male; D055806:Microvessels / Q000503:physiopathology; D008875:Middle Aged; D015999:Multivariate Analysis; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood*
chemical_list: D015415:Biomarkers; D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D014280:Triglycerides
keywords: diabetes mellitus; diabetic retinopathy; epidemiology; kidney; lipids; risk factors